top
Please input keywords
ニュース&PR
お問い合わせ
JP
CN
EN
KR
About us
会社情報
私たちの歩み
管理スタッフ
企業文化
社会的責任
共に働く
研究提携
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
動物・細胞モデル
Humanized animal models
KO mouse models
Tool mice
Immunodeficient mice/rats
Cell lines
Aged mice
Disease mouse models
Pharmacology service
Therapeutic area
Types of services
Molecule type
Technology
ゲノム編集
By species
By technologies
By strategies
Animal Breeding
Animal Cryopreservation
Animal Rederivation
Other Services
Microbial detection
Animal Breeding
Animal Cryopreservation
Animal Rederivation
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
About Us
研究提携
研究提携
オープン​イノベーションによる革新的な新薬の研究開発
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Antibody Out-licensing
Antibody Co-Development
Antibody Transfer
Technology Platform Out-licensing
Various drug modalities
Monoclonal Antibody
Bispecific Antibody
Bispecific ADC
Nanobodie
TCRm Antibody
Cell Therapy
Established partnerships
103
103 therapeutic antibody co-development/out-licensing/transfer agreements
47
47 target-nominated RenMice licensing projects
5
5 pipeline-based co-development
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Darmstadt, Germany, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.
Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.
+86-010-56967680
info@bbctg.com.cn
Copyright © 2024 Biocytogen. All Rights Reserved
Powered by Fractal-technology